A case report on rhACE2 treatment in a patients with severe COVID-19 confirmed the intended effect of a reduction in Ang II levels during twice daily intravenous treatment with rhACE2 for 7 days (Zoufaly et al., 2020). This evidence concerns the gene AGT and COVID-19.